Cite
Predictors of Ocrelizumab Effectiveness in Patients with Multiple Sclerosis
MLA
Simona Minguzzi, et al. Predictors of Ocrelizumab Effectiveness in Patients with Multiple Sclerosis. Jan. 2021. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....728e03d3ff4e4f5f86193aeadf231dcd&authtype=sso&custid=ns315887.
APA
Simona Minguzzi, Giovanni Novi, Antonio Uccelli, Alice Laroni, Giacomo Boffa, Federico Ivaldi, Nicolò Bruschi, Elisabetta Mancuso, Matilde Inglese, Gianluigi Mancardi, Elvira Sbragia, Caterina Lapucci, Maria Cellerino, Ilaria Poire, Francesco Tazza, & Elisabetta Capello. (2021). Predictors of Ocrelizumab Effectiveness in Patients with Multiple Sclerosis.
Chicago
Simona Minguzzi, Giovanni Novi, Antonio Uccelli, Alice Laroni, Giacomo Boffa, Federico Ivaldi, Nicolò Bruschi, et al. 2021. “Predictors of Ocrelizumab Effectiveness in Patients with Multiple Sclerosis,” January. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....728e03d3ff4e4f5f86193aeadf231dcd&authtype=sso&custid=ns315887.